Michael Goodman, MD
Hematology & Oncology · Winston Salem, NCNPI 1619020179
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $2,325 of the $3,756 with a category attached, or 61.9%. Astellas Pharma Global Development accounts for 63.7% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2020 at $2,325 and has fallen 94.5% since, to $128 in 2025.
Across 15 payments — averaging $250.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma Global Development$2K
- Merck$1K
- Regeneron Healthcare Solutions, Inc.$61
- Eisai Inc.$51
- Seagen Inc.$32
- Array Biopharma Inc$14
Across 182 payments — averaging $12,881 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$1.2M
- Astrazeneca UK Limited$306K
- Janssen Research & Development, LLC$150K
- Pfizer$147K
- Janssen Scientific Affairs, LLC$145K
- Genentech, Inc.$104K
- plus $249K from 6 others
What the payments were for
- Consulting fees$2,32562%
- Travel & lodging$97826%
- Food & beverage$3048%
- Education$1494%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma Global Development | 2 | $2,392 |
| Merck | 8 | $1,207 |
| Regeneron Healthcare Solutions, Inc. | 2 | $61 |
| Eisai Inc. | 1 | $51 |
| Seagen Inc. | 1 | $32 |
| Array Biopharma Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,756 in reported general payments places this provider in the 60th percentile of 358 hematology & oncology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NubeqaDarolutamide | 36 | $459,051 |
| ErleadaApalutamide | 13 | $193,371 |
| Abiraterone Acetate | 73 | $102,059 |
| OrgovyxRelugolix | 30 | $79,010 |
| Oxycodone Hcl | 11 | $676 |
| Prednisone | 69 | $138 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Winston Salem
- Angela AlistarWinston Salem$509K
- Ravi PaluriWinston Salem$314K
- Caio Max Rocha LimaWinston Salem$110K
- Timothy PardeeWinston Salem$68K
- Leon Bernal-MizrachiWinston Salem$62K
- Matthew WieduwiltWinston Salem$36K
- John McKayWinston Salem$22K
- Amit MehtaCary$4.3M
- Michael MorseDurham$2.6M
- Shelbi AtrashCharlotte$994K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.